This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
所属
This person is not affiliated with any business or Blue Board record at ProZ.com.
翻訳 - 英語 Promoting innovation by integrating SAP®, ERP and SAP NetWeaver® processes
Realizing maximum process efficiency through comprehensive process acceleration and the elimination of waste
◆The Challenge
The “Green Front Sakai” is an environmentally advanced factory combining the world's first “tenth generation” mother-glass substrate LCD panel manufacturing plant and the world's largest thin-film solar cell manufacturing plant. Sharp Corporation Ltd. (Sharp) and 19 co-operating component manufacturers act as virtually one company, integrating on-site production from raw materials to the finished panel. The affiliated LCD panel manufacturing plant began operating on the 1st of October 2009, built on the main concepts of “total waste elimination, accelerated process planning and maximization of managerial efficiency”.
Behind this conception was Sharp’s implementation of Service Oriented Architecture (SOA). SAP® ERP and SAP NetWeaver Process Integration (SAP NetWeaver PI) were at the core of this SOA.
◆The Solution
Only the most advanced techniques are implemented in the "Green Front Sakai" system. SAP ERP 6, the most up to date version of SAP ERP is used. Using ERP procurement, written order forms were eliminated and an "electronic screen system" was introduced to support supply functions between buildings. Delivery requests to partnering suppliers can now be generated automatically.
The Enterprise Manufacturing Execution System (Enterprise MES) optimized the functioning of the production facility’s workers, management, materials, and equipment by controlling the production process and ERP using Computer Integrated Manufacturing (CIM). SAP Netweaver PI with its ability to connect both systems was used to integrate the entire process.
SAP NetWeaver PI removes the need for user involvement and automates the data process from CIM to the Enterprise MES. Subsequently this data is sent from CIM to the Enterprise MES. Additionally, the flow of data can be automated up to the next level of Supply Chain Management. The construction of the system was developed using SOA between the IBM Business Consulting Services team and Sharp's subsidiary information company, SI Solutions Co. Ltd.
◆The Results
Compared to the previous factory model, the introduction of SAP ERP 6.0 and NetWeaver PI, not only enabled a reduction in inventory being achieved, but also the removal of data entry with the automation of document processing resulted in minimized human error. Input mistakes approached zero and the accuracy of data increased rapidly. Stock levels, sales figures and accounting information were all visible in real time which helped maximize operational efficiency. Furthermore, the previous factory model carried out procurement planning and production planning separately, one after the other, Green Front Sakai's consolidated system management contributed to a large 2/3 reduction in the lead time.
“It can be said the biggest effect of the introduction is the increased speed of the information. Stock levels, sales figures and accounting information all became visible in real time and did not have to be calculated based on previous days or weeks. Accordingly, it was possible to maximize managerial efficiency.”
翻訳 - 英語 The patient is a 75 year old female (height 155 cm, weight 65 kg). The patient was taking oral medication for diabetes, had a history of gall stones and had undergone an operation for uterine fibroids. There was no particular family history.
Late April, 2006
Administration of Drug A was begun to treat tenosynivitis. The day after administration the patient noticed back pain and general malaise.
Early May 2006, One week after treatment with Drug A commenced.
The patient received an examination from a local physician. Diffuse peritonitis was suspected due to an intestinal perforation and the patient was referred to this hospital. At the time of examination there was general softness of the abdominal area but muscular defense was noted on the left side. Also, blood tests showed WBC 9400/mm3, CRP 39.3 mg/dL and markedly elevated levels of CRP were observed. Stool culture tests revealed pathogenic bacteria. Abdominal and pelvic area CT revealed free air in a large area, including from the retroperitoneal membrane of both kidneys. Emergency surgery was performed for this reason. Perforations to the retroperitoneum were observed at one location on the transverse colon, and two locations on the descending colon. A colectomy was carried out on the left colon and a colostomy performed on the ascending colon.
Histopathological examination: There was visible irregular, discontinuous ulceration the descending colon and perforations were noted at one location on the transverse colon and two locations on the descending colon. Distribution of the lesions was not unusual. Mitosis and apoptotic bodies were observed by histology in the glandular epithelial cells of the lower intestinal crypt with non-specific inflammation.
**/May/2006
After the operation was carried out successfully the patient was transferred to another hospital after 17 days.
**/July/2006
A colonoscopy was performed 2 months after the operation and the remaining colon showed no recurrence of ulceration.
**/August/2006
The colostomy was closed 3 months after surgery.
**/**/2008.
There has been no recurrence of ulceration in the 29 months since surgery.
翻訳 - 英語 The Iron and Steel Institute of Japan. Excerpts of copyright regulations
Agreed by the Board of Directors on December 9, 2009
Effective as of March 1, 2010
Transfer of copyright
Article 6
Clause 2: The transfer of copyright from the author to this Institute will be established when the document with the author's signature noting the instructions for the transfer of copyright with the prescribed articles therein is received by this Institute.
However, in cases where the author agrees with the copyright regulations of this Institute and/or has not expressed any intent otherwise, the copyright will be transferred on submission of the work, or any copy thereof.
Clause 3: In cases where the subject of transfer is an edited work, upon transfer of copyright, the author of the edited work must have ascertained in advance that there is no infringement on the copyright relating to the original work at the time this Institute becomes the copyright holder.
Clause 4: In cases where the work subject to transfer of copyright is a joint work, all authors of the joint work agree to select a representative, who as an author, subject to “clause 2” and proceeding articles, will agree to the transfer of copyright on behalf of the other authors.
Article 11
Clause 1: The author’s responsibilities
The author, subject to the following terms and conditions, is responsible for intellectual property law and other laws, such as patent law, relating to the content of works created by the author for which this Institute holds the copyright.
Subject to the provisions of Article 6, Clause 2 to 4, the author who transferred copyright to the Institute.
Clause 2: Should a third party present a case against this Institute alleging infringement of copyright or a dispute arise from said infringement or an allegation of defamation of character from works created by the author for which the copyright, reproduction rights and/or permission to copyright has been transferred to this Institute, the author will bear legal responsibility and take action to resolve this dispute.
Clause 3: In cases where author and copyright holder are not one and the same, the “author” referred to in clause 1 and clause 2 will refer to the “copyright holder.”
原書のテキスト - 英語 Immunavex, the global leader in transfusion diagnostics, introduces our latest innovation. ImmunOp is Immunavex’s fourth generation, fully automated instrument for blood bank, and the next generation of instrumentation in the high volume segment of our Scalable Solutions. ImmunOp gives your laboratory the ability to achieve exceptional performance power, enhanced speed, and unprecedented flexibility. ImmunOp delivers a patient type and screen result in as little as 30 minutes or a high throughput of 180 pooled screens per hour. With the broadest immunohematology test menu on the market, this instrument will optimize your lab’s workflow and operational efficiencies by fully automating more of your work with trusted technologies that provide quality test results. Let’s get started with a tour of the instrument. I’ll provide a brief hardware tour of ImmunOp and we’ll also simulate test scheduling to demonstrate how our new STAT priority and optimized scheduler works.
Across, Adobe Acrobat, Dreamweaver, memoQ, Microsoft Excel, Microsoft Office Pro, Microsoft Word, Microsoft Powerpoint, Powerpoint, Passolo, Powerpoint, Trados Studio, TransSuite2000, Wordfast
入会時期 Sep '10
